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Introduction
============

Desmoplastic melanoma (DM) is a rare variant of melanoma and is considered a type of spindle cell tumor with high amounts of collagen \[[@REF1]\]. DM has an incidence of two per million, representing less than 4% of primary cutaneous melanoma diagnoses \[[@REF2]-[@REF3]\]. The presentation of this type of melanoma is unusual, and it is often difficult to detect \[[@REF4]\]. DM may mimic benign and malignant neoplasms, presenting as an indurated discoid, plaque, or nodule, frequently without pigmentation \[[@REF3]\]. Accordingly, the clinical diagnosis of this melanoma is challenging, resulting in infrequent misdiagnosis or underdiagnosis \[[@REF5]\]. DM is located more frequently in the head and neck, followed by the extremities and trunk \[[@REF6]\]. Surgical excision is the treatment of choice. However, given the described characteristics, these lesions are commonly detected when the depth of invasion is greater \[[@REF5]\]. As a consequence, the resection of the tumor becomes more difficult, increasing the likelihood of wider resections that result in greater disfigurement at the surgical site. Due to the low incidence of the disease, few studies have described the characteristics of DM, and no study compared them with those of common malignant melanoma (CMM) \[[@REF7]-[@REF14]\]. The aim of this study was to perform a comprehensive national analysis of the characteristics and survival rate of DM and to compare them with those of CMM in the US.

Materials and methods
=====================

This retrospective study utilized the National Cancer Database (NCDB) to identify DM cases registered between 2004 and 2015. The NCDB collects more than 70% of the new cancer cases in the US as part of the oncology hospital registry data. More than 34 million historical records are found in this database sponsored by the American College of Surgeons and the American Cancer Society \[[@REF15]\]. The clinical data provided within the NCDB was compiled under conditions of de-identification, with stringent integrity revision for quality reliability.

Inclusion and exclusion criteria

From 525,271 patients with all types of melanoma that were found in the NCDB database, we included only cases that were confirmed microscopically and classified as "desmoplastic melanoma" (n=5,895) and "malignant melanoma not otherwise specified" (n=292,939). "Malignant melanoma not otherwise specified" included patients with the histology type of melanoma not specified at diagnosis, considered common malignant melanoma (CMM) for the purpose of the study. Exclusion criteria included all the other histology types of melanoma different than DM and CMM (Figure [1](#FIG1){ref-type="fig"}).
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Variables

The variables analyzed in this study are described in Table [1](#TAB1){ref-type="table"}. Data abstracted from the database included demographic characteristics, such as age, sex, race, and year of diagnosis, and tumor characteristics, such as location, grade, and stage, Breslow depth, ulceration, surgery, radiation, regression, mitotic count, presence of lymph nodes positive, and brain, liver, and lung metastasis. For the multivariate regression analysis, tumor characteristics were considered independent variables except for the variable 'grade,' which was excluded due to the high number of cases with missing data. In addition, 4,284 DM and 265,187 CMM patients with missing data were excluded from the analysis. DM and CMM were considered our dependent variables of interest.

###### Definition of variables

  ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables           Definition
  Demographics         
  Age                 Age at diagnosis
  Sex                 Male or female
  Race                Race of the patient
  Comorbidities       Charlson Comorbidity Score. Yes: ≥ 1 Charlson Comorbidity Score. No: 0 Charlson Comorbidity Score
  Year at diagnosis   Year of initial diagnosis of the tumor, from 2004 to 2015
  Characteristics      
  Location            Location of the melanoma in the body
  Grade               Described the melanoma's resemblance to normal skin. Well-differentiated (grade I) was the most like normal tissue, and undifferentiated (grade IV) was the least like normal tissue
  Stage               Reported pathologic stage group or clinical stage group, if the pathologic stage was not reported
  Breslow depth       Thickness of the tumor\'s invasion
  Ulceration          Absence of intact epidermis overlying the primary melanoma based upon histopathological examination
  Radiation           Described if patients had any radiation therapy that was part of the first course of treatment
  Regression          Primary tumor regression documented in the pathology report
  Mitotic count       Number of mitotic figures found in one square millimeter (mm) surrounding either a \"hot spot\" with the most mitotic figures or a field with representative mitosis
  Lymph nodes         Records the presence or not of positive regional lymph nodes examined by the pathologist and found to contain metastases
  Brain metastasis    Brain metastasis at the time of diagnosis
  Liver metastasis    Liver metastasis at the time of diagnosis
  Lung metastasis     Lung metastasis at the time of diagnosis
  ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Statistical analysis

Tumor characteristics were compared using chi-square. Univariate and multivariate logistic regression were performed to determine the risk of tumor characteristics in patients with DM as compared to CMM and adjusted for age and sex. Adjusted odds ratio (aOR) was found to compare the groups. A comparison of the five-year overall survival (OS) curves between DM and CMM was performed. The independent variables analyzed for five-year OS for DM included sex, age, comorbidities, stage, location, Breslow depth, mitosis, ulceration, radiation, and presence of lymph nodes positive. Cases with unspecified and missing data were excluded for the survival analysis. Survival time in months was determined from the date of diagnosis to the date of death, date last known to be alive, or December 2015. Survival curves were estimated using the Kaplan-Meier method and were compared using log-rank tests to determine the statistical significance between the survival curves for DM and CMM. The multivariable Cox proportional hazard model was used to calculate the hazard ratios of the overall survival (OS) for DM. SPSS, version 25 (SPSS, Inc., IBM, Chicago, Illinois, US) was used for the analysis and P\<.05 was considered significant.

Results
=======

Demographic and tumor characteristics

The percentage of DM patients was 1.1% (5,895) over all types of melanoma. We found that there has been a higher percentage of cases of DM over time since 2010 as compared to CMM (Figure [2](#FIG2){ref-type="fig"}). The mean age of patients with DM was 68.37 years; most were white (97.91%), males (67.53%), and between 61 and 80 years old (50.64%) (Table [2](#TAB2){ref-type="table"}).
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###### Demographic characteristics of patients with Desmoplastic Melanoma and Common Malignant Melanoma

  ----------------------------- ----------------------- --------------------------- --------------- ------- ------
  Demographic Characteristics   Desmoplastic Melanoma   Common Malignant Melanoma   P Value                 
  Total N=5,895                 Total N=292, 939                                                            
  n                             \%                      n                           \%                      
  Age                                                                                                        
  Mean (SD)                     68.37 (14.09)           \-                          61.17 (16.09)   \-      \-
  Median                        70                      \-                          62              \-      \-
  Range                         (7-90)                  \-                          (0-90)          \-      \-
  Age group                                                                                                 
  \<40 years                    215                     3.65                        30,791          10.51    
  40-60 years                   1,414                   23.99                       102,465         34.98    
  61-80 years                   2,985                   50.64                       125,707         42.91    
  \>80 years                    1,281                   21.73                       33,976          11.60    
  Sex                                                                                                       
  Male                          3,981                   67.53                       165,749         56.58    
  Female                        1,914                   32.47                       127,190         43.42    
  Race                                                                                                      0.18
  White                         5,772                   97.91                       284,369         97.07    
  Black                         43                      0.73                        1,821           0.62     
  Other                         36                      0.61                        2,308           0.79     
  Unknown                       44                      0.75                        4,441           1.52     
  Year of diagnosis                                                                                         
  2004-2006                     1,184                   20.08                       63,943          21.83    
  2007-2009                     1,293                   21.93                       70,941          24.22    
  2010-2012                     1,564                   26.53                       74,204          25.33    
  2013-2015                     1,854                   31.45                       83,851          28.62    
  ----------------------------- ----------------------- --------------------------- --------------- ------- ------

DM was more frequently found in the scalp and neck (24.17%), of grade III (0.64%) and stage II (55.15%), with a Breslow depth of more than 4 mm (35.44%), a mitotic count of 1 mitosis/mm^2^ or more (32.25%), negative lymph nodes (61.97%), and without any ulceration (78.56%) or regression (42.27%). On the other hand, CMM was more frequently located in the trunk (28.25%), of grade III (0.54%) and stage I (36.12%), with a Breslow depth of less than or equal to 1 mm (35.14%), negative lymph nodes (27.41%), a mitotic count of 1 mitosis/mm^2^ or more (13.10%), and without any ulceration (71.06%) or regression (28.84%) (Table [3](#TAB3){ref-type="table"}).

###### Tumor characteristics of patients with Desmoplastic Melanoma and Common Malignant Melanoma

  --------------------------------------- ----------------------- --------------------------- --------- ------- ------
                                          Desmoplastic Melanoma   Common Malignant Melanoma   P Value           
                                          Total N=5,895           Total N=292,939                               
                                          n                       \%                          n         \%      
  Location                                                                                                      
  Lips                                    87                      1.48                        722       0.25     
  Eyelid                                  29                      0.49                        1,485     0.51     
  External ear                            182                     3.09                        8,875     3.03     
  Other parts of face, site unspecified   1,447                   24.55                       35,209    12.02    
  Scalp and neck                          1,425                   24.17                       22,976    7.84     
  Trunk                                   1,024                   17.37                       82,764    28.25    
  Upper extremities and shoulder          1,314                   22.29                       68,082    23.24    
  Lower extremities and hip               297                     5.04                        50,403    17.21    
  Overlapping lesion of skin              14                      0.24                        350       0.12     
  Skin, site unspecified                  76                      1.29                        22,073    7.54     
  Grade                                                                                                         .002
  Grade I                                 9                       0.15                        1,083     0.37     
  Grade II                                8                       0.14                        788       0.27     
  Grade III                               38                      0.64                        1,585     0.54     
  Grade IV                                14                      0.24                        490       0.17     
  Cell type not determined                5,826                   98.83                       288,993   98.65    
  Stage                                                                                                         
  Stage 0                                 40                      0.68                        90,983    31.06    
  Stage I                                 1,576                   26.73                       105,810   36.12    
  Stage II                                3,251                   55.15                       27,247    9.3      
  Stage III                               390                     6.62                        20,571    7.02     
  Stage IV                                156                     2.65                        18,499    6.31     
  Unknown                                 482                     8.18                        29,829    10.18    
  Breslow depth                                                                                                 
  ≤1 mm                                   1,051                   17.83                       102,950   35.14    
  1.01- 2 mm                              1,079                   18.3                        32,632    11.14    
  2.01-4mm                                1,331                   22.58                       18,310    6.25     
  \>4 mm                                  2,089                   35.44                       12,362    4.22     
  Unknown                                 345                     5.85                        126,685   43.25    
  Ulceration                                                                                                    
  No                                      4,631                   78.56                       211,096   72.06    
  Yes                                     862                     14.62                       28,347    9.68     
  Unknown                                 402                     6.82                        53,493    18.26    
  Surgery                                                                                                       
  No, diagnosed at autopsy                92                      1.56                        22,890    7.81     
  Yes                                     5,798                   98.35                       268,861   91.78    
  Unknown                                 5                       0.08                        1,188     0.41     
  Radiation                                                                                                     
  No                                      4,964                   84.21                       278,907   95.21    
  Yes                                     899                     15.25                       11,865    4.05     
  Unknown                                 32                      0.54                        2,167     0.74     
  Regression                                                                                                    
  No                                      2,492                   42.27                       84,497    28.84    
  Yes                                     132                     2.24                        10,143    3.46     
  Unknown                                 3,219                   54.61                       194,816   66.5     
  Mitotic count                                                                                                 
  No presence of mitosis                  733                     12.43                       35,897    12.25    
  \<1 mitosis/mm^2^                       239                     4.05                        7,293     2.49     
  ≥1 mitosis/mm^2^                        1,901                   32.25                       38,376    13.10    
  Unknown                                 2,970                   50.38                       207,891   70.97    
  Lymph nodes                                                                                                   
  Negative                                3,653                   61.97                       80,296    27.41    
  Positive                                339                     5.75                        23,428    8        
  Unknown                                 1,903                   32.28                       189,215   64.59    
  Brain metastasis                                                                                              
  No                                      3,376                   57.27                       150,251   51.29    
  Yes                                     8                       0.14                        3,391     1.16     
  Unknown                                 2,511                   42.6                        139,297   47.55    
  Liver metastasis                                                                                              
  No                                      3,374                   57.23                       151,499   51.72    
  Yes                                     10                      0.17                        2,077     0.71     
  Unknown                                 2,511                   42.6                        139,363   47.57    
  Lung metastasis                                                                                               
  No                                      3,338                   56.62                       149,532   51.05    
  Yes                                     46                      0.78                        4,049     1.38     
  Unknown                                 2,511                   42.6                        139,358   47.57    
  --------------------------------------- ----------------------- --------------------------- --------- ------- ------

Regarding therapy, most of the DM (98.35%) and CMM (91.78%) patients underwent surgery. Furthermore, most of DM (84.21%) and CMM (95.21%) patients did not receive radiation to their lesions. With respect to metastasis, most of the cases in both types of melanoma did not have metastasis at diagnosis, although for DM patients, the most common metastasis, when it was found, was lungs (0.78%), followed by liver (0.17%), and brain (0.14%) metastasis, respectively (Table [3](#TAB3){ref-type="table"}).

Tumor characteristics comparison

One-thousand six-hundred and eleven cases with DM and 27,752 cases with CMM were analyzed to compare tumor characteristics. We found that DM was more likely to be diagnosed in patients older than 80 years (adjusted odds ratio (aOR), 3.57; 95% confidence interval (CI), 2.59-4.91; P\<.001), stage IV (aOR, 9.85; 95% CI, 2.11-46.00; P=.004), with a Breslow depth of greater than 4 mm (aOR,7.63; 95% CI, 5.95-9.80; P\<.001); and be treated with radiation (aOR, 6.03; 95% CI, 4.78-7.62; P\<.001), as compared to CMM. On the other hand, DM was less likely to present in the lower extremities and hip (aOR, 0.06; 95%CI, 0.003-0.13; P\<.001), have ulceration (aOR, 0.28; 95% CI, 0.24-0.33; P\<.001), present regression (aOR, 0.45; 95% CI, 0.35-0.58; P\<.001), have a mitotic count of 1 mitosis/mm^2^ or more (aOR, 0.35; 95% CI, 0.30-0.41; P\<.001), present lymph node involvement (aOR, 0.32; 95% CI, 0.21-0.48; P\<.001), and metastasis to the brain at diagnosis (aOR, 0.11; 95% CI, 0.01-0.97; P=.047), as compared to CMM (Table [4](#TAB4){ref-type="table"}, Figure [3](#FIG3){ref-type="fig"}). We did not find a statistical difference between DM and CMM regarding sex, surgery, and metastasis to the liver and lungs.

###### Univariate and multivariate analysis of factors associated with Desmoplastic Melanoma

Abbreviations: OR, odds ratio; aORs, adjusted odds ratios

\*Reference value

\*\*Only aORs associated with a CI not crossing 1.0 are shown

  --------------------------------------- --------------------- ----------------------- --------- ---------- ------------ ---------
                                          Univariate Analysis   Multivariate Analysis                                     
  Variables                               OR                    95% CI                  P Value   aORs\*\*   95% CI       P Value
  Age                                                                                                                      
  \< 40 years                             1.00\*                \-                      \-        1.00\*     \-           \-
  40-60 years                             2.31                  1.74-3.07                         2.2        1.63-2.97    
  61-80 years                             4.5                   3.43-5.91                         3.09       2.31-4.14    
  \>80 years                              6.27                  4.67-8.41                         3.57       2.59-4.91    
  Sex                                                                                                                      
  Male                                    1.00\*                \-                      \-        1.00\*     \-           \-
  Female                                  0.63                  0.56-0.70                         \-         \-           \-
  Location                                                                                                                 
  Lip                                     1.00\*                \-                      \-        1.00\*     \-           \-
  Eyelid                                  0.16                  0.04-0.56               .005      \-         \-           \-
  External ear                            0.16                  0.09-0.28                         0.27       0.13-0.56    
  Other parts of face, site unspecified   0.37                  0.22-0.64                         \-         \-           \-
  Scalp and neck                          0.38                  0.22-0.65                         0.49       0.25-0.97    .04
  Trunk                                   0.08                  0.05-0.14                         0.18       0.09-0.36    
  Upper extremities and shoulder          0.12                  0.07-0.21                         0.24       0.12-0.47    
  Lower extremities and hip               0.03                  0.01-0.05                         0.06       0.03-0.13    
  Stage                                                                                                                    
  Stage 0                                 1.00\*                \-                      \-        1.00\*     \-           \-
  Stage I                                 4.9                   1.57-15.31              .006      5.14       1.26-20.92   .02
  Stage II                                24.83                 7.97-77.39                        13.99      3.42-57.28   
  Stage III                               3.92                  1.24-12.38              .02       5.69       1.32-24.49   .02
  Stage IV                                11.74                 3.46-39.83                        9.85       2.11-46.00   .004
  Breslow depth                                                                                                            
  ≤1 mm                                   1.00\*                \-                      \-        1.00\*     \-           \-
  1.01-2 mm                               1.72                  1.44-2.04                         2.03       1.69-2.43    
  2.01-4 mm                               4.07                  3.44-4.81                         2.86       2.22-3.69    
  \>4 mm                                  9.35                  7.98-10.96                        7.63       5.95-9.80    
  Ulceration                                                                                                               
  No                                      1.00\*                \-                      \-        1.00\*     \-           \-
  Yes                                     0.55                  0.48-0.63                         0.28       0.24-0.33    
  Surgery                                                                                                                  
  No, diagnosed at autopsy                1.00\*                \-                      \-        1.00\*     \-           \-
  Yes                                     1.23                  0.3-5.09                .77       \-         \-           \-
  Radiation                                                                                                                
  No                                      1.00\*                \-                      \-        1.00\*     \-           \-
  Yes                                     7.81                  6.65-9.19                         6.03       4.78-7.62    
  Regression                                                                                                               
  No                                      1.00\*                \-                      \-        1.00\*     \-           \-
  Yes                                     0.38                  0.30-0.48                         0.45       0.36-0.58    
  Mitotic count                                                                                                            
  No presence of mitosis                  1.00\*                \-                      \-        1.00\*     \-           \-
  \<1 mitosis/mm^2^                       0.84                  0.69-1.04               .11       0.74       0.58-0.94    .01
  ≥1 mitosis/mm^2^                        0.65                  0.57-0.73                         0.35       0.3-0.41     
  Lymph nodes                                                                                                              
  Negative                                1.00\*                \-                      \-        1.00\*     \-           \-
  Positive                                0.31                  0.26-0.38                         0.32       0.21-0.48    
  Brain metastasis                                                                                                         
  No                                      1.00\*                \-                      \-        1.00\*     \-           \-
  Yes                                     0.46                  0.06-3.34               .44       0.11       0.01-0.97    .047
  Liver metastasis                                                                                                         
  No                                      1.00\*                \-                      \-        1.00\*     \-           \-
  Yes                                     0.74                  0.18-3.06               .68       \-         \-           \-
  Lung metastasis                                                                                                          
  No                                      1.00\*                \-                      \-        1.00\*     \-           \-
  Yes                                     1.86                  0.97-3.58               .06       \-         \-           \-
  --------------------------------------- --------------------- ----------------------- --------- ---------- ------------ ---------
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Survival analysis

Patients with DM had a five-year OS rate of 75 %, whereas patients with CMM had a five-year OS rate of 76 %. Figure [4](#FIG4){ref-type="fig"} demonstrates the Kaplan Meier survival curves (log rank, P\<.07). The multivariable Cox proportional model revealed that age at diagnosis (hazard ratio (HR), 1.06; 95% CI, 1.04-1.07; P\<.001) and presence of comorbidities (HR, 2.08; 95% CI, 1.56-2.77; P\<.001) were independent positive predictors of OS in patients with DM while the location of the DM in the upper extremities and shoulder was found to reduce the risk of the overall death in these patients (HR, 0.61; 95% CI, 0.43-0.87; P=0.01) (Table [5](#TAB5){ref-type="table"}).
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###### Cox proportional hazard regression analysis of prognostic factors for Overall Survival in patients with Desmoplastic Melanoma

Abbreviations: HR, hazard ratio

\*Reference value

  ------------------------------------------------------------------------------------------------------- ----------------------- ---------
                                                                                                          Desmoplastic Melanoma   
  Characteristic                                                                                          HR (95% CI)             P Value
  Age                                                                                                     1.06 (1.04-1.07)        
  Sex                                                                                                                              
  Male                                                                                                    1.00\*                   
  Female                                                                                                  0.73 (0.52-1.01)        .06
  Comorbidities                                                                                                                    
  No                                                                                                      1.00\*                   
  Yes                                                                                                     2.08 (1.56-2.77)        
  Location                                                                                                                         
  Head and neck (lips, eyelid, external ear, other parts of face, site unspecified, and scalp and neck)   1.00\*                   
  Trunk                                                                                                   0.75 (0.52-1.07)        .11
  Upper extremities and shoulder                                                                          0.61 (0.43-0.87)        .01
  Lower extremities and hip                                                                               0.78 (0.37-1.64)        .51
  Breslow depth                                                                                                                    
  ≤1 mm                                                                                                   1.00\*                   
  1.01-2 mm                                                                                               1.22 (0.70 -2.12)       .48
  2.01-4 mm                                                                                               0.80 (0.44-1.47)        .48
  \>4 mm                                                                                                  1.52 (0.88-2.63)        .14
  Stage                                                                                                                            
  Stage 0                                                                                                 1.00\*                   
  Stage I                                                                                                 0.20 (0.03-1.61)        .13
  Stage II                                                                                                0.32 (0.04-2.35)        .26
  Stage III                                                                                               0.39 (0.05-3.13)        .37
  Stage IV                                                                                                0.88 (0.11-7.20)        .91
  Lymph nodes                                                                                                                      
  Negative                                                                                                1.00\*                   
  Positive                                                                                                1.94 (0.97-3.89)        .06
  Ulceration                                                                                                                       
  No                                                                                                      1.00\*                   
  Yes                                                                                                     1.12 (0.81-1.55)        .49
  Radiation                                                                                                                        
  No                                                                                                      1.00\*                   
  Yes                                                                                                     0.71 (0.50-1.02)        .06
  Mitotic count                                                                                                                    
  No presence of mitosis                                                                                  1.00\*                   
  \<1 mitosis/mm^2^                                                                                       1.05 (0.58-1.91)        .87
  ≥1 mitosis/mm^2^                                                                                        1.29 (0.90-1.83)        .16
  ------------------------------------------------------------------------------------------------------- ----------------------- ---------

Discussion
==========

DM is considered an uncommon subtype melanoma with a frequency of 1% to 4% \[[@REF14]\]. In our study, we found that DM corresponded to 1.1% of the total types of melanoma reported on the NCDB. This low frequency of DM is concerning, as this could be related to a misdiagnosis of the disease; however, the increase in the percentage of cases reported over the years may indicate a decreasing trend in misdiagnosis. It may also be a result of the efforts for early detection and the increase in total cases of melanoma \[[@REF16]\]. The female-to-male ratio found in this study was approximately 1:2, as it was previously found by Xu et al. \[[@REF17]\]. Concerning the demographic characteristics, most of the patients with DM were white men over the age of 80, as is typically found in patients with CMM \[[@REF18]\].

In our study, the most frequent locations of DM were the head and neck, specifically the scalp and neck, followed by the upper limbs, shoulders, and trunk. This differs from our findings regarding CMM, which was most often found in the trunk, followed by the face and the upper limbs and shoulders. These differences may be linked to a change in clothing, lifestyle habits, and chronic ultraviolet exposure independent of the type of melanoma \[[@REF19]\]. DM is often located in places that are not easily seen, which might be an additional factor associated with delayed diagnosis. Furthermore, DM is also challenging to diagnose due to the difficulty to recognize the melanoma-associated patterns \[[@REF20]\], its variable appearance, and the absence of pigmentation \[[@REF4],[@REF21]\].

Our study showed that DM patients presented at diagnosis with higher grades, advanced stage, and deeper Breslow depth (≥4 mm) when compared with patients affected by CMM. Moreover, radiation therapy was more likely to be given to patients with DM, probably due to the delay in diagnosis and its high propensity to recur, as this type of treatment is reserved for unresectable cases, and to prevent the recurrence of the disease \[[@REF10],[@REF19]\].

Associations of high mitotic rates with the presence of positive sentinel lymph nodes, higher rates of recurrence, and lower survival rates have been demonstrated in CMM \[[@REF22]-[@REF23]\]. In our study, we found that DM patients had less risk to have an increased count of mitosis compared to CMM, suggesting that DM has a better prognosis than CMM. Other predictors of prognosis previously described are the presence of ulceration and sentinel lymph nodes \[[@REF24]\]. The presence of ulceration favors the dissemination of the tumor after modifying the local environment of the DM in the skin and directly impacts the rates of survival \[[@REF22],[@REF25]\]. In our study, DM lesions were less likely to have ulceration as compared to CMM and to influence the death rates of DM patients.

Currently, regression and its relationship with prognosis are controversial. Some studies suggest that regression is an indicator of poor prognosis \[[@REF26]\] while others propose that it is related to better outcomes \[[@REF27]\]. Our study showed that regression is more likely to occur in CMM than in DM.

Sentinel lymph node biopsy allows the detection of micrometastasis in the regional lymph nodes with high sensitivity and specificity and is also a prognostic factor of survival \[[@REF23]\]. In the present study, DM patients had less risk of lymph node involvement as compared to CMM patients. This finding supports the idea that DM is related to fewer metastases to lymph nodes (rate of 0%-15%) as previously described by Andreevscaia et al. \[[@REF4]\]. In addition, Sims et al. found that metastases to regional lymph nodes were less common to appear in DM of the head and neck as compared to CMM \[[@REF28]\].

Systemic metastases are not frequent in DM, affecting the lung, liver, and bone in 7% to 44% of patients \[[@REF10]\]. In our study, we found that the most frequent metastasis was the lung (0.78%), followed by the liver (0.17%) and brain (0.14%). Probably, the rates of metastases were overestimated due to the lower number of DM cases reported in the literature compared with the total number of DM cases described in our study.

In the survival analysis, the five-year OS in patients with DM was 75%, without any statistical difference with CMM. Previously, Khan et al. found a five-year OS of 79.5% in patients with DM of the head and neck, diagnosed from 1992 to 2013 \[[@REF3]\]. The difference in these OS rates may be due to the high number of cases presented in our analysis. In our analysis, the DM survival rate was determined by the advanced age and the presence of comorbidities in the patients analyzed.

Known prognostic factors like Breslow depth, ulceration, mitosis, and lymph nodes involvement were not associated to increase the risk of death, probably due to the survival being related to other causes of death, and not specifically to DM \[[@REF29]\].

There are some important limitations to this study related to the source of data from the NCDB. In particular, our results were dependent on the information compiled in the database, which was not always complete. In an effort to obtain the most accurate results possible, we excluded missing information that could affect the models. Furthermore, as all the database information is provider dependent, some cases of DM could have been misclassified. For this reason, we considered the variable 'histology' to define the DM and CMM cases confirmed by the pathologist. Regarding the survival curves, we were unable to address the disease-specific survival because the NCDB did not allow us to obtain this information. However, the OS gave us an approximation of the survival of these DM patients. Despite these limitations, we believe this study reports a valuable analysis of the demographics and tumor characteristics of DM patients. Moreover, the comparison of DM with CMM gives us an orientation of the aggressiveness of the disease and underscores the importance of an early diagnosis. However, further prospective studies are needed to better explain the progression and biology of DM.

Our findings support the idea that DM continues being misdiagnosed or diagnosed at a more advanced stage of the disease despite the increasing rate of diagnosis over time. Older age, advanced stage, higher Breslow depth, and radiation therapy were more likely to be present in DM patients as compared to CMM. This study gives significant insights into this very rare type of melanoma. Surgeons should be aware of DM and its characteristics in order to control the burden of the disease and to improve management strategies in the future.

Conclusions
===========

Our study suggests that DM probably continues being diagnosed at a more advanced stage of the disease, despite its prevalence over time. Older age, advanced stage, higher Breslow depth, and radiation therapy were more likely to be present in DM patients as compared to CMM. This study gives significant insights into this very rare type of melanoma. Surgeons should be aware of DM and its characteristics in order to control the burden of the disease and to improve management strategies in the future.
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